Business Description
Nektar Therapeutics
NAICS : 325412
SIC : 2834
ISIN : US6402681083
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.58 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 0.9 | |||||
Debt-to-EBITDA | -0.48 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -12.57 | |||||
Beneish M-Score | -2.73 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -17.9 | |||||
3-Year EBITDA Growth Rate | 16.5 | |||||
3-Year EPS without NRI Growth Rate | 30.5 | |||||
3-Year FCF Growth Rate | 17.2 | |||||
3-Year Book Growth Rate | -51.5 | |||||
Future 3-5Y Total Revenue Growth Rate | -10.98 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 72.99 | |||||
9-Day RSI | 67.72 | |||||
14-Day RSI | 65.91 | |||||
6-1 Month Momentum % | 157.55 | |||||
12-1 Month Momentum % | 76.08 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.45 | |||||
Quick Ratio | 6.14 | |||||
Cash Ratio | 5.92 | |||||
Days Inventory | 197.5 | |||||
Days Sales Outstanding | 11.11 | |||||
Days Payable | 70.11 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2 | |||||
Shareholder Yield % | 4.64 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 62.53 | |||||
Operating Margin % | -150.05 | |||||
Net Margin % | -306.31 | |||||
FCF Margin % | -214.62 | |||||
ROE % | -126.07 | |||||
ROA % | -52.95 | |||||
ROIC % | -127.22 | |||||
ROC (Joel Greenblatt) % | -444.45 | |||||
ROCE % | -53.97 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 3.46 | |||||
PB Ratio | 2.4 | |||||
Price-to-Tangible-Book | 2.4 | |||||
EV-to-EBIT | -0.46 | |||||
EV-to-EBITDA | -0.47 | |||||
EV-to-Revenue | 1.28 | |||||
EV-to-Forward-Revenue | 1.35 | |||||
EV-to-FCF | -0.6 | |||||
Price-to-Median-PS-Value | 0.33 | |||||
Price-to-Net-Current-Asset-Value | 4.95 | |||||
Price-to-Net-Cash | 8.52 | |||||
Earnings Yield (Greenblatt) % | -217.39 | |||||
FCF Yield % | -64.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Nektar Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 83.616 | ||
EPS (TTM) (€) | -1.358 | ||
Beta | 1.62 | ||
Volatility % | 87.9 | ||
14-Day RSI | 65.91 | ||
14-Day ATR (€) | 0.072114 | ||
20-Day SMA (€) | 1.3429 | ||
12-1 Month Momentum % | 76.08 | ||
52-Week Range (€) | 0.3901 - 1.646 | ||
Shares Outstanding (Mil) | 183.62 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Nektar Therapeutics Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Nektar Therapeutics Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Nektar Therapeutics Frequently Asked Questions
What is Nektar Therapeutics(FRA:ITH)'s stock price today?
When is next earnings date of Nektar Therapeutics(FRA:ITH)?
Does Nektar Therapeutics(FRA:ITH) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |